Investor relations

Cyxone is a lean company

Cyxone is a lean, virtual company focused on developing T20K against Multiple Sclerosis (MS). T20K has passed the research stage, which reduces the time to key value-added activities such as clinical trials.

T20K's effects in cell and animal studies suggest that the drug may become a breakthrough product for MS patients.

Cyxone is seeking a commercial partner that may accelerate clinical development and  increase the company’s value. Cyxone also intends to develop new pharmacologically active cyclotides for major diseases such as rheumatoid arthritis which provides opportunities for long-term value creation.

9/28/2017

VD Kjell Stenberg presenterar Cyxone på BioStock Live i Stockholm

Financial calendar

Interim Report Q3 2017
October 25, 2017
Year End Report 2017
February 16, 2018